PORPHOBILINOGEN PBG QUALITATIVE URINE Test
Test Details:
The Porphobilinogen (PBG) Qualitative Urine Test is a diagnostic test used to detect the presence of porphobilinogen in the urine. Porphobilinogen is an intermediate compound in the heme synthesis pathway, and its accumulation can be indicative of certain porphyrias, a group of rare genetic disorders that affect the production of heme.
During the test, a urine sample is collected from the patient and analyzed in the laboratory. The urine is mixed with a reagent that reacts with porphobilinogen, producing a characteristic color change. The intensity of the color change is then compared to a standard color chart to determine the presence and concentration of porphobilinogen in the urine.
A positive result indicates the presence of porphobilinogen in the urine, suggesting a possible diagnosis of acute intermittent porphyria (AIP) or other related porphyrias. A negative result indicates the absence of porphobilinogen and may rule out these conditions.
It is important to note that the PBG Qualitative Urine Test is a screening test and does not provide a definitive diagnosis. Further confirmatory tests, such as the measurement of porphobilinogen deaminase activity or genetic testing, may be required to confirm the diagnosis of a specific porphyria.
Test Components and Price:
- Test Name: PORPHOBILINOGEN PBG QUALITATIVE URINE Test
- Components: Column Chromatography
- Price: 820.0 AED
Sample Condition:
10 mL (5 mL min.) aliquot of random urine collected in a dark coloured vial/container wrapped completely with black paper or aluminium foil. Ship refrigerated or frozen. Uncovered vials exposed to light are unacceptable.
Report Delivery:
Sample: Tue / Fri by 9 am
Report: Same day
Test Type and Doctor:
Test Type: Porphyria
Doctor: Physician
Test Department:
BIOPHYSICS
Pre Test Information:
Collect urine in a dark coloured vial/container wrapped completely with black paper or aluminium foil.
Symptoms and Diagnosis:
The PBG Qualitative Urine Test is typically ordered when a patient presents with symptoms suggestive of a porphyria, such as abdominal pain, neuropathy, and skin photosensitivity. It may also be used for monitoring the effectiveness of treatment in patients with known porphyria.
It is essential to consult with a healthcare provider or a specialist in metabolic disorders to interpret the test results accurately and determine the appropriate course of action based on the patient’s clinical presentation and medical history.
| Test Name | PORPHOBILINOGEN PBG QUALITATIVE URINE Test |
|---|---|
| Components | |
| Price | 820.0 AED |
| Sample Condition | 10 mL (5 mL min.) aliquot of random urinecollectedinadarkcolouredvial\/ container wrapped completely with black paper or aluminium foil. Ship refrigeratedor frozen. Uncovered vials exposed to light are unacceptable. |
| Report Delivery | SampleTue / Fri by 9 am;Report Same day |
| Method | Column Chromatography |
| Test type | Porphyria |
| Doctor | Physician |
| Test Department: | BIOPHYSICS |
| Pre Test Information | Collect urine in a darkcolouredvial/ container wrapped completely with black paper or aluminium foil. |
| Test Details |
The Porphobilinogen (PBG) Qualitative Urine Test is a diagnostic test used to detect the presence of porphobilinogen in the urine. Porphobilinogen is an intermediate compound in the heme synthesis pathway, and its accumulation can be indicative of certain porphyrias, a group of rare genetic disorders that affect the production of heme. During the test, a urine sample is collected from the patient and analyzed in the laboratory. The urine is mixed with a reagent that reacts with porphobilinogen, producing a characteristic color change. The intensity of the color change is then compared to a standard color chart to determine the presence and concentration of porphobilinogen in the urine. A positive result indicates the presence of porphobilinogen in the urine, suggesting a possible diagnosis of acute intermittent porphyria (AIP) or other related porphyrias. A negative result indicates the absence of porphobilinogen and may rule out these conditions. It is important to note that the PBG Qualitative Urine Test is a screening test and does not provide a definitive diagnosis. Further confirmatory tests, such as the measurement of porphobilinogen deaminase activity or genetic testing, may be required to confirm the diagnosis of a specific porphyria. The test is typically ordered when a patient presents with symptoms suggestive of a porphyria, such as abdominal pain, neuropathy, and skin photosensitivity. It may also be used for monitoring the effectiveness of treatment in patients with known porphyria. It is essential to consult with a healthcare provider or a specialist in metabolic disorders to interpret the test results accurately and determine the appropriate course of action based on the patient’s clinical presentation and medical history. |
